title: Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
abstract: A patient with high fever, loss of weight and profound pancytopenia is reported. Peripheral T-cell lymphoma with hemophagocytosis was diagnosed. Bone marrow was the only localisation of the lymphoma. At presentation there were (i) a coagulopathy consistent with hemophagocytic histiocytosis (ii) the features of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). These different abnormalities disappeared after chemotherapy and reappeared during each of the 2 periods of disease progression. The patient died 6 months after diagnosis without ever achieving complete remission. As far as we are aware this is the first case report of T-cell lymphoma with hemophagocytic syndrome localised to the bone marrow and associated with SIADH.
authors.affiliation: Laboratoire Central d'Hématologie, Hôpital Hôtel-Dieu, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Ciaudo
authors.forename: L
authors.initials: L
authors.lastname: Chauvenet
authors.forename: J
authors.initials: J
authors.lastname: Audouin
authors.forename: J
authors.initials: J
authors.lastname: Rossert
authors.forename: R
authors.initials: R
authors.lastname: Favier
authors.forename: M H
authors.initials: MH
authors.lastname: Horellou
authors.forename: A
authors.initials: A
authors.lastname: Bernadou
authors.forename: M
authors.initials: M
authors.lastname: Samama
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D001855:Bone Marrow Diseases / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007177:Inappropriate ADH Syndrome / Q000209:etiology*; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D008935:Mitoguazone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D013713:Teniposide / Q000008:administration & dosage; D014700:Verapamil / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D014700:Verapamil; D008935:Mitoguazone; D002945:Cisplatin; D014751:Vindesine; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate